U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07855276) titled 'A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS' on Sept. 28.
Brief Summary: This study aims to better understand how Bruton's tyrosine kinase (BTK) inhibition with remibrutinib works in hidradenitis suppurativa (HS), a complex inflammatory disease with different types of lesions.
Study Start Date: Oct. 14
Study Type: INTERVENTIONAL
Condition:
Hidradenitis Suppurativa
Intervention:
DRUG: LOU064
Remibrutinib
DRUG: Placebo
matching placebo
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Novartis Pharmaceuticals
Disclaimer: Curated by HT Syndication....